SCHEMBL557898

SCHEMBL557898

Cc1ccc2nc(Cl)cnc2c1

nearest known ligand 0.62

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.62
NQO2 P16083 1/20 0.50
MAPT P10636 4/20 0.44
LMNA P02545 3/20 0.44
RAB9A P51151 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
NPC1 O15118 1/20 0.44
EGFR P00533 1/20 0.44
MAPK1 P28482 1/20 0.44
KDM4E B2RXH2 3/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
TDP1 Q9NUW8 1/20 0.42
CYP1A2 P05177 3/20 0.41
KMT2A Q03164 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
HRH4 Q9H3N8 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL559386 0.92 ALDH1A1 (0.62) ALDH1A1NQO2MAPTLMNARAB9A
SCHEMBL6844954 0.79 CYP1A2 (0.54) ALDH1A1NQO2MAPTLMNARAB9A
SCHEMBL29639043 0.79 CYP1A2 (0.54) ALDH1A1NQO2MAPTLMNARAB9A
SCHEMBL29580471 0.79 ALDH1A1 (0.55) ALDH1A1MAPTLMNARAB9ASMN1; SMN2
SCHEMBL346120 0.79 ALDH1A1 (0.55) ALDH1A1MAPTLMNARAB9ASMN1; SMN2
Toluene SCHEMBL28417697 0.79 ALDH1A1 (0.51) ALDH1A1NQO2MAPTLMNARAB9A
Ammonia Solution, Strong SCHEMBL28148393 0.78 ALDH1A1 (0.53) ALDH1A1MAPTLMNARAB9ASMN1; SMN2
SCHEMBL6216217 0.77 ALDH1A1 (1.00) ALDH1A1NQO2MAPTRAB9ASMN1; SMN2
SCHEMBL780275 0.76 ALDH1A1 (0.52) ALDH1A1LMNASMN1; SMN2KDM4EL3MBTL1
SCHEMBL12647372 0.76 ALDH1A1 (0.52) ALDH1A1RAB9ASMN1; SMN2NPC1HRH4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101735158-B Preparation method of 2, 3-dimercapto-6-methylquinoxaline NANJING UNIVERSITY OF TECHNOLOGY 2011-08-31 CN claimed
CN-101735158-A Preparation method of 2, 3-dimercapto-6-methylquinoxaline NANJING UNIVERSITY OF TECHNOLOGY 2010-06-16 CN claimed
WO-2020065613-A1 MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2020-04-02 WO disclosed
CN-108191778-A It treats different things alike the method for preparing 2,3- dichloro-quinoxaline derivatives 重庆医科大学 2018-06-22 CN disclosed
CN-108084425-A Makrolon and preparation method thereof, polycarbonate compositions or blend and its application 万华化学集团股份有限公司 2018-05-29 CN disclosed
US-9822108-B2 Antimicrobial agents RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2017-11-21 US disclosed
US-9822108-B2 Antimicrobial agents RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2017-11-21 US disclosed
US-9822108-B2 Antimicrobial agents RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2017-11-21 US disclosed
US-20160101104-A1 QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS BRISTOL MYERS SQUIBB CO (US) 2016-04-14 US disclosed
US-20150342935-A1 QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS BRISTOL MYERS SQUIBB CO (US) 2015-12-03 US disclosed
CN-103524436-B 1-[(the alkoxyl group quinoxalinyl that 6,7-replaces) aminocarboxyl]-4-(mixing) aryl piperazine derivative REXAHN PHARMACEUTICALS INC. (US) 2015-09-23 CN disclosed
CN-101903372-A Heteroaryl derivatives as orexin receptor antagonists HOFFMANN LA ROCHE 2010-12-01 CN disclosed
CN-101735158-A Preparation method of 2, 3-dimercapto-6-methylquinoxaline NANJING UNIVERSITY OF TECHNOLOGY 2010-06-16 CN disclosed
US-20100099684-A1 Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands BRISTOL-MYERS SQUIBB COMPANY 2010-04-22 US disclosed
US-20090270405-A1 QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS BRISTOL-MYERS SQUIBB COMPANY 2009-10-29 US disclosed
WO-2009131926-A1 QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS BRISTOL-MYERS SQUIBB COMPANY (US) 2009-10-29 WO disclosed
WO-2007087250-A2 TRICYCLIC INHIBITORS OF 5-LIPOXYGENASE AMIRA PHARMACEUTICALS, INC. (US) 2007-08-02 WO disclosed
US-20070173508-A1 TRICYCLIC INHIBITORS OF 5-LIPOXYGENASE AMIRA PHARMACEUTICALS, INC. (US) 2007-07-26 US disclosed
US-20070173508-A1 TRICYCLIC INHIBITORS OF 5-LIPOXYGENASE AMIRA PHARMACEUTICALS, INC. (US) 2007-07-26 US disclosed
EP-0046468-A1 Quinoxaline derivatives and herbicidal composition NISSAN CHEMICAL INDUSTRIES LTD. (JP) 1982-03-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100099684-A1 Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands CHRNA7, CHRNA5, CHRNA6 ALDH1A1 1082/4885NQO2 130/4885MAPT 268/4885
US-20070173508-A1 TRICYCLIC INHIBITORS OF 5-LIPOXYGENASE ALOX5, ALOX15, ALOX15B ALDH1A1 802/4885NQO2 649/4885MAPT 4706/4885
US-20090270405-A1 QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS CHRNA7, CHRNA5, CHRNA6 ALDH1A1 1082/4885NQO2 130/4885MAPT 268/4885
US-20160101104-A1 QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS CHRNA7, CHRNA5, CHRNA6 ALDH1A1 1082/4885NQO2 130/4885MAPT 268/4885
US-20150342935-A1 QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS CHRNA7, CHRNA5, CHRNA6 ALDH1A1 1082/4885NQO2 130/4885MAPT 268/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.